Natalizumab

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Portaccio (control exposed to IFN), 2018 15.51[1.10; 27.66]954not evaluable Major congenital malformations Portaccio (control exposed to IFN), 2018 12.88[0.25; 32.65]354not evaluable Minor congenital malformations Portaccio (control exposed to IFN), 2018 17.65[0.87; 67.50]654not evaluable Growth parameters and prematurity Preterm (< 37 weeks) Portaccio (control exposed to IFN), 2018 Nguyen (control unexposed, sick), 2019 20.84[0.46; 1.52]235111not evaluable Low birth weight (< 2500g) 0----- Maternal consequences Caesarean 0----- Maternal consequences (as a whole) Portaccio (control exposed to IFN), 2018 13.50[1.02; 12.05]1354not evaluable Intrauterine deaths Elective/induced termination of pregnancy Portaccio (control exposed to IFN), 2018 Nguyen (control unexposed, sick), 2019 22.26[0.33; 15.52]48147not evaluable Intrauterine deaths (as a whole or unspecified) Nguyen (control unexposed, sick), 2019 11.63[0.74; 3.58]5878not evaluable Early intrauterine death (< 22 weeks) Portaccio (control exposed to IFN), 2018 12.44[0.90; 6.57]1969not evaluable Ectopic pregnancy Portaccio (control exposed to IFN), 2018 11.28[0.03; 65.21]-69not evaluable Late intrauterine deaths (> 22 weeks) Portaccio (control exposed to IFN), 2018 10.42[0.02; 10.50]169not evaluable Neuro-developmental disorders Neuro-developmental disorders (as a whole) Portaccio (control unexposed, sick), 2018 16.37[0.88; 46.18]454not evaluable0.0100.01.0